Walleye Capital LLC Acquires 118,430 Shares of Haemonetics Corporation $HAE

Walleye Capital LLC increased its stake in shares of Haemonetics Corporation (NYSE:HAE) by 152.0% during the second quarter, HoldingsChannel reports. The fund owned 196,361 shares of the medical instruments supplier’s stock after acquiring an additional 118,430 shares during the quarter. Walleye Capital LLC’s holdings in Haemonetics were worth $14,650,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of HAE. Cary Street Partners Financial LLC acquired a new stake in Haemonetics in the 1st quarter worth $1,082,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Haemonetics by 0.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 556,027 shares of the medical instruments supplier’s stock valued at $35,336,000 after buying an additional 4,834 shares during the period. Citigroup Inc. grew its position in Haemonetics by 87.3% during the first quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier’s stock worth $39,755,000 after buying an additional 291,574 shares in the last quarter. Zions Bancorporation National Association UT bought a new position in Haemonetics during the first quarter valued at about $2,744,000. Finally, Global Alpha Capital Management Ltd. raised its holdings in Haemonetics by 61.1% in the 1st quarter. Global Alpha Capital Management Ltd. now owns 27,553 shares of the medical instruments supplier’s stock valued at $1,751,000 after acquiring an additional 10,452 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Price Performance

HAE opened at $83.78 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. The stock has a market capitalization of $3.92 billion, a P/E ratio of 24.50, a price-to-earnings-growth ratio of 1.47 and a beta of 0.30. The company’s 50 day simple moving average is $61.12 and its 200-day simple moving average is $63.74. Haemonetics Corporation has a one year low of $47.31 and a one year high of $85.00.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.15. The firm had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. Haemonetics’s revenue was down 5.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Sell-side analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HAE. BTIG Research reissued a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a report on Friday, November 21st. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Mizuho dropped their price objective on shares of Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. Raymond James Financial reiterated an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a research report on Friday, November 14th. Finally, Needham & Company LLC lifted their price objective on Haemonetics from $68.00 to $78.00 and gave the company a “buy” rating in a report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $79.70.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.